Meda AB
 | |
| OTCPK:MDABY | |
| Headquarters | , Sweden |
| Revenue | >SKr 15,000,000,000 (2014) |
Number of employees | 5,202 (2014) |
| Parent | Mylan  |
Meda AB is an international specialty pharmaceutical company, headquartered in Solna, Sweden. Sales at the end of 2014 amounted to more than SKr 15,000,000,000, making it the 48th largest pharmaceutical company in the world. At the end of 2014, Meda had 5,202 employees. Meda's pharmaceuticals are sold in more than 150 countries.[1]
Meda has been listed since 1995 on the Stockholm stock market and is currently part of the Nasdaq OMX Nordic 120 index, though not of the OMX Nordic 40.[2]
Mergers, acquisitions and divestments
In 2014, Meda acquired the Italian firm RottaPharm Madaus in order to add consumer health products to their portfolio.[3] Meda explored in 2015 the possibility of divesting its United States division, Meda Pharmaceuticals, to raise funds for expansion in other areas.[3]
| Meda |
| |||||||||
References
- ^ "About Meda". Meda AB. Retrieved 15 August 2015.[self-published source]
- ^ "Index info NOMXN120, NASDAQ OMX NORDIC 120, (SE0003270875)". Indexes. Nasdaq OMX. Retrieved 15 August 2015.
- ^ a b Ewing, Adam; Baigorri, Manuel (27 August 2015). "Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations". Bloomberg Business. Retrieved 28 August 2015.